Compare ZYME & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | ENVX |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2017 | N/A |
| Metric | ZYME | ENVX |
|---|---|---|
| Price | $26.43 | $7.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $32.75 | $17.14 |
| AVG Volume (30 Days) | 589.6K | ★ 6.0M |
| Earning Date | 11-06-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,481,000.00 | $30,273,000.00 |
| Revenue This Year | $63.57 | $36.91 |
| Revenue Next Year | $89.45 | $117.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 116.21 | 45.98 |
| 52 Week Low | $9.03 | $5.27 |
| 52 Week High | $28.49 | $16.49 |
| Indicator | ZYME | ENVX |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 46.83 |
| Support Level | $26.10 | $7.21 |
| Resistance Level | $26.91 | $8.58 |
| Average True Range (ATR) | 0.95 | 0.48 |
| MACD | -0.25 | 0.01 |
| Stochastic Oscillator | 49.84 | 36.48 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.